FABP4 and obesity due to melanocortin 4 receptor deficiency: Moreover, FABP4 inhibitors have also been proposed as potential therapies for lipid disorders, particularly high triglycerides, acute kidney injury, obesity-related cancer, obesity, and diabetes [17,23,24,25].